Ondine Biomedical is a leading life sciences company that has developed a unique, patented platform technology to revolutionise infection control and address a broad spectrum of infections in healthcare and industry settings. The Company recently came to market in an AIM IPO, raising US$30m to drive approval and commercialisation of its key photodisinfection technology, with numerous applications and multi-billion dollar markets to address.
